Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC

Triple Negative Breast Cancer - Twitter Chat

Certification period for this program has expired.
No credit will be offered beyond the program dates noted on the bottom of this page.


This activity is jointly provided by Global Education Group and Bonum CE.

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Program Overview

In just over the past two years, the introduction of immune checkpoint inhibitor therapy, antibody-drug conjugates, and poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors, marks a new era in triple-negative breast cancer (TNBC) treatment. This recent expansion of TNBC therapies has practice-changing implications for how clinicians’ approach TNBC treatment.

This CME-certified, Twitter-based live virtual chat will allow participants and faculty to discuss the recent expansion of therapies and their practice-changing implications for how clinicians’ approach TNBC treatment, focusing on how to help close some of the practice barriers and deficits reported with molecular testing and optimal TNBC treatment.

Faculty

Aditya Bardia, MD, MPH
Attending Physician
Director, Breast Cancer Research
Department of Medical Oncology
Massachusetts General Hospital Cancer Center
Associate Professor, Harvard Medical School
Boston, MA

Rebecca Shatsky, MD
Associate Professor of Medicine
Director Inflammatory and Triple-Negative Breast Cancer Program,
Breast Medical Oncology Co-Team Leader
Department of Hematology – Oncology
UC San Diego
La Jolla, CA

Target Audience

Medical, surgical, radiation oncologists, pathologists, fellows, trainees, and advanced practice professionals caring for patients with TNBC.

Learning Objectives

After completing this activity series, the participant should be better able to:

  • IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC

  • SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with TNBC

  • IDENTIFY strategies for optimizing second line therapy for patients with mTNBC

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

 

  • Aditya Bardia, MD, MPH
    Consulting: Astra Zeneca, Daiichi Sankyo Inc., Eli Lilly, Foundation Medicine, Genentech, Gilead, Merck, Novartis, Pfizer, Phillips, Radius Health, Sanofi
    Contracted Research: Astra Zeneca, Daiichi Sankyo Inc., Eli Lilly, Genentech, Gilead, Merck, Novartis, Pfizer, Radius Health, Sanofi

    Rebecca Shatsky, MD
    Consulting: OncoSec Immunotherapies
    Contracted Research    : CytomX Therapeutics, Genentech/Roche, OncoSec Immunotherapies, Pfizer, Phoenix Molecular Designs
    Honoraria: The Dedham Group
    Speaker’s Bureau: Gilead

  • Lindsay Borvansky
    Nothing to disclose

    Ashley Cann
    Nothing to disclose

    Bonum CE staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Certification

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Bonum Continuing Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit & Fee Information

In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 75% on the post-test, complete the evaluation and application for credit form.

There is no fee to participate in this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group, collaborators, and faculty on this program do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

All Bonum CE digital activities require the following hardware/software to view and participate:

  • Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)

  • PowerPoint and/or a PDF viewer may be required on some activities

We recommend a minimum of:

  • 128MB RAM

  • Processor speed of 500MHz or higher

  • 800x600 color monitor

  • Video or graphics card

  • Sound card and speakers

To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Release date: October 18, 2022
Expiration date: October 18, 2023
Estimated time to complete activity: 60 minutes